VJHemOnc’s video series on CART cells interviewing Michael Hudecek
During the EBMT-EHA 4th European CAR T-cell Meeting, VJHemOnc interviewed Michael Hudecek, MD, University of Würzburg, Würzburg, Germany on several exciting CAR-T topics. Watch the videos below, produced by the fantastic VJHemOnc team.
CARAMBA-1: a Phase I/IIa trial of autologous SLAMF7 CAR-Ts in multiple myeloma
Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, outlines the rationale and preliminary results of CARAMBA-1, an ongoing Phase I/IIa clinical trial evaluating the feasibility, safety and anti-myeloma activity of autologous SLAMF7 chimeric antigen T-cells (CAR-T) in patients with multiple myeloma (NCT04499339). Recent pre-clinical studies have demonstrated that CAR-Ts targeting SLAMF7 have potent anti-myeloma efficacy. Early results from the dose-escalation part of the CARAMBA-1 study suggest that these CAR-Ts are safe and show indications of anti-tumor activity. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting in which was held virtually in 2022.
Young EBMT & EHA Ambassadors: the basic science behind CAR-Ts
Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, outlines the aims and key points of his talk in the Young EBMT & EHA Ambassadors session. This session is dedicated to young clinicians and scientists and aims to explain the basic science behind chimeric antigen receptor T-cells (CAR-Ts), how they were transformed into a viable product, and how CAR-Ts are evaluated. The session will also highlight clinical data on CAR-Ts. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
CAR-T trials and research at UKW
Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, gives an update of the chimeric antigen receptor T-cell (CAR-T) clinical trials and research conducted at the University Hospital of Würzburg (UKW). Dr Hudecek talks on the ongoing CARAMBA-1 trial evaluating autologous SLAMF7 CAR-Ts in multiple myeloma (NCT04499339), and comments on a novel promising target antigen for CAR-T therapy in acute myeloid leukemia (AML). He also explains that a clinical trial for a CAR-T product for breast cancer and lung cancer will be launched soon. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
EBMT-EHA CAR T-cell meeting: all the latest in CAR-T
Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, gives an overview of the EBMT-EHA 4th European CAR T-cell Meeting program, highlighting the aims and importance of this meeting. Chimeric antigen receptor T-cell (CAR-T) therapy is one of the most rapidly evolving fields in translational research. The EBMT-EHA CAR T-cell meeting brings key opinion leaders (KOLs) and stakeholders from all over the world together to discuss the latest data in CAR-T therapies and exchange ideas to further improve this practice-changing technology. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Exploring the applications of CAR-Ts beyond hematology and oncology
Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, discusses the potential of engineered immune cell therapies such as chimeric antigen receptor T-cells (CAR-Ts) in fields other than hematology and oncology, namely infectious diseases, auto-immune diseases, and cardiovascular diseases. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
